FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

James Murray

Research Profile

Chemicals & Drugs

Disorders

Anatomy

Co-author Network

Publications

TOP 3
James L Murray; Mala Pande; Aysegul A Sahin; Patricia Thompson; Suk Young Yoo; Renke Zhou; Melissa L Bondy; Kim-Anh Do; Yanhong Liu; Abenaa M Brewster
Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer.
Francisco J Esteva; Ana M Gonzalez-Angulo; Marjorie C Green; Gabriel N Hortobagyi; Kimberly B Koenig; Mong-Hong Lee; Stacy L Moulder; James L Murray; Joe Ensor; Sai-Ching Yeung
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.
Stacy Moulder; James L Murray; Edgardo Rivera; Daniel Booser; Abeena Brewster; Massimo Cristofanilli; Joe Ensor; Sharon H Giordano; Gregory Gladish; Ana Maria Gonzalez-Angulo; Gabriel N Hortobagyi; Julia Moore; Hai T Tran
A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of James Murray (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: James L Murray; Mala Pande; Aysegul A Sahin; Patricia Thompson; Suk Young Yoo; Renke Zhou; Melissa L Bondy; Kim-Anh Do; Yanhong Liu; Abenaa M Brewster
Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer.
Breast cancer research and treatment 2013;138(3):917-24.
2013: Francisco J Esteva; Ana M Gonzalez-Angulo; Marjorie C Green; Gabriel N Hortobagyi; Kimberly B Koenig; Mong-Hong Lee; Stacy L Moulder; James L Murray; Joe Ensor; Sai-Ching Yeung
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.
Cancer chemotherapy and pharmacology 2013;71(1):63-72.
2012: Stacy Moulder; James L Murray; Edgardo Rivera; Daniel Booser; Abeena Brewster; Massimo Cristofanilli; Joe Ensor; Sharon H Giordano; Gregory Gladish; Ana Maria Gonzalez-Angulo; Gabriel N Hortobagyi; Julia Moore; Hai T Tran
A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.
Cancer 2012;118(9):2378-84.
2012: Takayuki Iwamoto; Kimberly Koenig; Junji Matsuoka; James L Murray; Daniel J Booser; Francisco J Esteva; Christos Hatzis; Gabriel N Hortobagyi; Yuan Qi; Weiwei Shi; W Fraser Symmans; Naoto T Ueno; Vicente Valero; Elliana J Yang; Jie Zhang; Lajos Pusztai
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(7):729-34.
2011: Elizabeth A Mittendorf; James L Murray; Gheath Alatrash; G Travis Clifton; Haile Xiao; George E Peoples
Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials.
Expert review of vaccines 2011;10(6):755-74.
2010: Y C Cheng; V Valero; M L Davis; M C Green; A M Gonzalez-Angulo; Richard L Theriault; James L Murray; Gabriel N Hortobagyi; Naoto T Ueno
Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients.
British journal of cancer 2010;103(9):1331-4.
2010: Gabriel N Hortobagyi; Robyn R Young; Mark Karwal; Nuhad K Ibrahim; Robert Hermann; James L Murray; Stanley P Watkins; Ira Gore
A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer.
Cancer 2010;116(10):2301-6.
2007: Abenaa Brewster; Kim-Anh Do; Patricia A Thompson; Karin M E Hahn; Aysegul A Sahin; Yumei Cao; Maureen M Stewart; James L Murray; Gabriel N Hortobagyi; Melissa L Bondy
Relationship between epidemiologic risk factors and breast cancer recurrence.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(28):4438-44.
2006: Clay L Efferson; Naotake Tsuda; Kouichiro Kawano; Estanislao Nistal-Villán; Shankhar Sellappan; Dihua Yu; James L Murray; Adolfo García-Sastre; Constantin G Ioannides
Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells.
Journal of virology 2006;80(1):383-94.
2005: Kouichiro Kawano; Clay L Efferson; George E Peoples; Darrick Carter; Naotake Tsuda; James L Murray; Constantin G Ioannides
Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death.
Cancer research 2005;65(7):2930-7.
2004: James L Murray; Michael E Gillogly; Kouichiro Kawano; Clay L Efferson; Jeffrey E Lee; Merrick Ross; Xinhui Wang; Soldano Ferrone; Constantin G Ioannides
Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma.
Cancer research 2004;64(15):5481-8.
2004: Byung K Ko; Clay L Efferson; Kouichiro Kawano; Henry M Kuerer; Aysegul Sahin; James L Murray; Constantin G Ioannides
Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes.
International journal of oncology 2004;24(6):1413-8.
2004: Michael E Gillogly; Nikoletta L Kallinteris; Minzhen Xu; Joseph V Gulfo; Robert E Humphreys; James L Murray
Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer.
Cancer immunology, immunotherapy : CII 2004;53(6):490-6.
2004: Apostolia-Maria Tsimberidou; James L Murray; Susan O'Brien; William G Wierda; Michael J Keating
Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome.
Cancer 2004;100(10):2195-200.
2003: Lajos Pusztai; Jim Hou Zhen; Banu Arun; Edgardo Rivera; Clark Whitehead; W Joseph Thompson; Kimberly M Nealy; Amy Gibbs; W Fraser Symmans; Francisco J Esteva; Daniel J Booser; James L Murray; Vicente Valero; Terry L Smith; Gabriel N Hortobagyi
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(18):3454-61.
2003: Byung K Ko; Kouichiro Kawano; James L Murray; Mary L Disis; Clay L Efferson; Henry M Kuerer; George E Peoples; Constantin G Ioannides
Clinical studies of vaccines targeting breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(9):3222-34.
2003: Jonathan Trent; Vicente Valero; Daniel J Booser; Laura Guerra; Nuhad Ibrahim; Zia Rahman; Laurent Vernillet; Shreyaskumar Patel; Cynthia L David; James L Murray; Massimo Cristofanilli; Gabriel N Hortobagyi
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2426-34.
2003: Nuhad K Ibrahim; James L Murray
Clinical development of the STn-KLH vaccine (Theratope).
Clinical breast cancer 2003;3 Suppl 4():S139-43.
2002: James L Murray; Michael E Gillogly; Donna Przepiorka; Hannah Brewer; Nuhad K Ibrahim; Daniel J Booser; Gabriel N Hortobagyi; Andrzej P Kudelka; Kenneth H Grabstein; Martin A Cheever; Constantin G Ioannides
Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(11):3407-18.
2002: Sharon H Giordano; Daniel J Booser; James L Murray; Nuhad K Ibrahim; Zia Rahman; Vicente Valero; Richard L Theriault; Marguerite F Rosales; Edgardo Rivera; Debra Frye; Michael S Ewer; Nelson G Ordonez; Aman U Buzdar; Gabriel N Hortobagyi
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(11):3360-8.
2002: Agapito Castilleja; Darrick Carter; Clay L Efferson; Nancy E Ward; Kouichiro Kawano; Bryan Fisk; Andrzej P Kudelka; David M Gershenson; James L Murray; Catherine A O'Brian; Constantin G Ioannides
Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(7):3545-54.
2002: Bita Esmaeli; James L Murray; M Amir Ahmadi; Aresu Naderi; Sanjay Singh; Jorge Romaguera; Christine White; Peter McLaughlin
Immunotherapy for low-grade non-hodgkin secondary lymphoma of the orbit.
Archives of ophthalmology 2002;120(9):1225-7.
2002: Henry M Kuerer; George E Peoples; Aysegul A Sahin; James L Murray; S Eva Singletary; Agapito Castilleja; Kelly K Hunt; David M Gershenson; Constantin G Ioannides
Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2002;22(5):583-92.
2002: Francisco J Esteva; Vicente Valero; Daniel J Booser; Laura T Guerra; James L Murray; Lajos Pusztai; Massimo Cristofanilli; Banu Arun; Bita Esmaeli; Herbert A Fritsche; Nour Sneige; Terry L Smith; Gabriel N Hortobagyi
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(7):1800-8.
2002: Nuhad K Ibrahim; Zia Rahman; Vicente Valero; James L Murray; Debra Frye; Gabriel N Hortobagyi
Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer.
Cancer investigation 2002;20(1):29-37.
2001: Massimo Cristofanilli; Aman U Buzdar; Nour Sneige; Terry Smith; BJ Wasaff; Nuhad Ibrahim; Daniel J Booser; Edgardo Rivera; James L Murray; Vicente Valero; Naoto T Ueno; Eva Singletary; Kelly Hunt; Eric A Strom; Marsha D McNeese; Carol B Stelling; Gabriel N Hortobagyi
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma.
Cancer 2001;92(7):1775-82.
2001: Gabriel N Hortobagyi; Naoto T Ueno; Weiya Xia; S Zhang; Judith K Wolf; Joe B Putnam; P L Weiden; Jie S Willey; M Carey; D L Branham; J Y Payne; SD Tucker; Chandra Bartholomeusz; RG Kilbourn; Robert L De Jager; Nour Sneige; Ruth Katz; Pervin Anklesaria; Nuhad K Ibrahim; James L Murray; Richard L Theriault; Vicente Valero; David M Gershenson; M W Bevers; Leaf Huang; Gabriel Lopez-Berestein; Mien-Chie Hung
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(14):3422-33.
2001: Edgardo Rivera; Vicente Valero; L Syrewicz; Zia Rahman; Francisco J Esteva; Richard L Theriault; Marguerite Rosales; Daniel J Booser; James L Murray; Robert C Bast; Gabriel N Hortobagyi; F L Esteva
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1716-22.
2001: Nuhad K Ibrahim; Vicente Valero; Zia Rahman; Richard L Theriault; Ronald S Walters; Aman U Buzdar; Daniel J Booser; Frankie A Holmes; James L Murray; Jie Willey; Robert C Bast; Gabriel N Hortobagyi
Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation.
Cancer investigation 2001;19(5):459-66.
2001: Agapito Castilleja; Nancy E Ward; Catherine A O'Brian; B Swearingen; Eric A Swan; MA Gillogly; James L Murray; Andrzej P Kudelka; David M Gershenson; Constantin G Ioannides
Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity.
Molecular and cellular biochemistry 2001;217(1-2):21-33.
2000: James L Murray; D Przepiorka; Constantin G Ioannides
Clinical trials of HER-2/neu-specific vaccines.
Seminars in oncology 2000;27(6 Suppl 11):71-5; discussion 92-100.
2000: James L Murray
Monoclonal antibody treatment of solid tumors: a coming of age.
Seminars in oncology 2000;27(6 Suppl 11):64-70; discussion 92-100.
2000: BW Anderson; George E Peoples; James L Murray; MA Gillogly; David M Gershenson; Constantin G Ioannides
Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(11):4192-200.
2000: BW Anderson; Andrzej P Kudelka; T Honda; M S Pollack; David M Gershenson; MA Gillogly; James L Murray; Constantin G Ioannides
Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides.
Cancer immunology, immunotherapy : CII 2000;49(9):459-68.
2000: Marjorie C Green; James L Murray; Gabriel N Hortobagyi
Monoclonal antibody therapy for solid tumors.
Cancer treatment reviews 2000;26(4):269-86.
2000: Tom V Lee; BW Anderson; George E Peoples; Agapito Castilleja; James L Murray; David M Gershenson; Constantin G Ioannides
Identification of activated tumor antigen-reactive CD8+ cells in healthy individuals.
Oncology reports 2000;7(3):455-66.
2000: Tom V Lee; D K Kim; George E Peoples; Agapito Castilleja; James L Murray; David M Gershenson; Constantin G Ioannides
Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2000;20(4):391-401.
2000: James L Murray; JM Hudson; M I Ross; H Z Zhang; Constantin G Ioannides
Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: relationship to TAP expression.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(1):28-35.
1999: George E Peoples; BW Anderson; Tom V Lee; James L Murray; Andrzej P Kudelka; J Taylor Wharton; Constantin G Ioannides
Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4214-23.
1999: Nuhad K Ibrahim; Zia Rahman; Vicente Valero; Jie Willey; Richard L Theriault; Aman U Buzdar; James L Murray; Robert C Bast; Gabriel N Hortobagyi
Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma.
Cancer 1999;86(7):1251-7.
1999: D K Kim; Tom V Lee; Agapito Castilleja; BW Anderson; George E Peoples; Andrzej P Kudelka; James L Murray; T Sittisomwong; J Taylor Wharton; J W Kim; Constantin G Ioannides
Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients.
Anticancer research 1999;19(4B):2907-16.
1999: Michael G Rosenblum; Claire F Verschraegen; James L Murray; Andrzej P Kudelka; Jacalyn B Gano; Lawrence Cheung; John J Kavanagh
Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(5):953-61.
1998: B Babcock; BW Anderson; Ioannis Papayannopoulos; Agapito Castilleja; James L Murray; Stefano Stifani; Andrzej P Kudelka; J Taylor Wharton; Constantin G Ioannides
Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the Notch complex.
Molecular immunology 1998;35(17):1121-33.
1998: Michael William Pride; S Shuey; A Grillo-Lopez; G Braslawsky; Merrick Ross; Sewa S Legha; Omar Eton; Antonio C Buzaid; C Ioannides; James L Murray
Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2363-70.
1998: Mansoor N Saleh; D Y Lalisan; Michael William Pride; A Solinger; M S Mayo; Albert F LoBuglio; James L Murray
Immunologic response to the dual murine anti-Id vaccine Melimmune-1 and Melimmune-2 in patients with high-risk melanoma without evidence of systemic disease.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(5):379-88.
1998: T M Tuttle; BW Anderson; W E Thompson; Jeffrey E Lee; Aysegul Sahin; Terry L Smith; Kenneth H Grabstein; J Taylor Wharton; Constantin G Ioannides; James L Murray
Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):2015-24.
1998: JM Hudson; Agapito Castilleja; James L Murray; T Honda; Andrzej P Kudelka; Eva Singletary; J Taylor Wharton; Constantin G Ioannides
Growth and antigen recognition of tumor-infiltrating lymphocytes from human breast cancer.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1998;18(7):529-36.
1997: D J Macey; E J Grant; LeelapP Kasi; Michael G Rosenblum; Hua-Zhong Zhang; Ruth Katz; P T Rieger; D LeBherz; M South; J W Greiner; J Schlom; Donald A Podoloff; James L Murray
Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(9):1547-55.
1997: Sekhar M Pothireddy; R M Harwood; D F Moore; Elizabeth A Grimm; James L Murray; Saroj Vadhan-Raj
Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: a phase 1 study.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(1):79-87.
1997: Bryan Fisk; JM Hudson; John Kavanagh; J Taylor Wharton; James L Murray; Constantin G Ioannides; Andrzej P Kudelka
Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides.
Anticancer research 1997;17(1A):45-53.
1997: Bryan Fisk; BW Anderson; KR Gravitt; Catherine A O'Brian; Andrzej P Kudelka; James L Murray; J Taylor Wharton; Constantin G Ioannides
Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes.
Cancer research 1997;57(1):87-93.
1996: R Sirisriro; Donald A Podoloff; Yehuda Z Patt; Steven A Curley; L P Kasi; V A Bhadkamkar; E Edmund Kim; James L Murray; R Smith; T P Haynie
99Tcm-IMMU4 imaging in recurrent colorectal cancer: efficacy and impact on surgical management.
Nuclear medicine communications 1996;17(7):568-76.
1996: James L Murray; Eugenie S Kleinerman; Shu-Fang Jia; Michael G Rosenblum; Omar Eton; Antonio C Buzaid; Sewa S Legha; Merrick I Ross; L Thompson; K Mujoo; P T Rieger; M Saleh; M B Khazaeli; S Vadhan-Raj
Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(3):206-17.
1996: Michael G Rosenblum; L Cheung; S K Kim; K Mujoo; Nicholas J Donato; James L Murray
Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells.
Cancer immunology, immunotherapy : CII 1996;42(2):115-21.
1995: James L Murray; D J Macey; E J Grant; Michael G Rosenblum; L P Kasi; Hua-Zhong Zhang; Ruth Katz; P T Riger; D LeBherz; V Bhadkamkar
Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment.
Cancer research 1995;55(23 Suppl):5925s-5928s.
1995: Bryan Fisk; Cherylyn A Savary; JM Hudson; Catherine A O'Brian; James L Murray; J Taylor Wharton; Constantin G Ioannides
Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(4):197-209.
1995: Kapil Dhingra; H Fritsche; James L Murray; A F LoBuglio; M B Khazaeli; S Kelley; Mark Tepper; D Grasela; Aman U Buzdar; Vicente Valero
Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin.
Cancer research 1995;55(14):3060-7.
1995: K Mujoo; L Cheung; James L Murray; Michael G Rosenblum
Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin.
Cancer immunology, immunotherapy : CII 1995;40(5):339-45.
1995: Michael G Rosenblum; L Cheung; K Mujoo; James L Murray
An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models.
Cancer immunology, immunotherapy : CII 1995;40(5):322-8.
1994: Michael G Rosenblum; B Levin; M Roh; D Hohn; R McCabe; L Thompson; L Cheung; James L Murray
Clinical pharmacology and tissue disposition studies of 131I-labeled anticolorectal carcinoma human monoclonal antibody LiCO 16.88.
Cancer immunology, immunotherapy : CII 1994;39(6):397-400.
1994: James L Murray; Michael G Rosenblum; Hua-Zhong Zhang; Donald A Podoloff; L P Kasi; Steven A Curley; J C Chan; M Roh; D C Hohn; H Brewer
Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients.
Cancer 1994;73(3 Suppl):850-7.
1994: James L Murray; D J Macey; L P Kasi; P Rieger; Joan E. Cunningham; V Bhadkamkar; Hua-Zhong Zhang; J Schlom; Michael G Rosenblum; Donald A Podoloff
Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer.
Cancer 1994;73(3 Suppl):1057-66.
1994: James L Murray; Joan E. Cunningham; H Brewer; K Mujoo; A A Zukiwski; Donald A Podoloff; L P Kasi; V Bhadkamkar; Herbert A Fritsche; Robert S Benjamin
Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(1):184-93.
1994: Kapil Dhingra; H Fritsche; James L Murray; A F LoBuglio; M B Khazaeli; S Kelley; Mark Tepper; D Greene; Daniel J Booser; Aman U Buzdar
Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study.
Advances in experimental medicine and biology 1994;353():193-202.
1993: K Mujoo; Nicholas J Donato; Ruth Lapushin; Michael G Rosenblum; James L Murray
Tumor necrosis factor alpha and gamma-interferon enhancement of anti-epidermal growth factor receptor monoclonal antibody binding to human melanoma cells.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(3):166-74.
1992: P J Schilling; James L Murray; A B Markowitz
Novel tumor necrosis factor toxic effects. Pulmonary hemorrhage and severe hepatic dysfunction.
Cancer 1992;69(1):256-60.
1991: Kyogo Itoh; Charles M Balch; James L Murray; D R Parkinson; A B Markowitz; Moshe Talpaz; K Lee; A A Zukiwski; Merrick I Ross; Sewa S Legha
Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies.
In vivo (Athens, Greece) 1991;5(6):647-53.
1991: L M Lamki; Aman U Buzdar; S E Singletary; Michael G Rosenblum; V Bhadkamkar; L Esparza; Donald A Podoloff; A Zukiwski; G N Hortobagyi; James L Murray
Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1991;32(7):1326-32.
1991: K Mujoo; Michael G Rosenblum; James L Murray
Augmented binding of radiolabeled monoclonal antibodies to melanoma cells using specific antibody combinations.
Cancer research 1991;51(11):2768-72.
1991: Michael G Rosenblum; James L Murray; L Cheung; R Rifkin; S Salmon; R Bartholomew
A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin.
Molecular biotherapy 1991;3(1):6-13.
1991: James L Murray; K Mujoo; C Wilmanns; P Mansfield; D S Wilbur; Michael G Rosenblum
Variables influencing tumor uptake of anti-melanoma monoclonal antibodies radioiodinated using para-iodobenzoyl (PIB) conjugate.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1991;32(2):279-87.
1991: Kyogo Itoh; K Hayakawa; M A Salmeron; Sewa S Legha; James L Murray; Moshe Talpaz; Charles M Balch; D R Parkinson; K Lee; A A Zukiwski
Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy.
Cancer immunology, immunotherapy : CII 1991;33(4):238-46.
1991: Michael G Rosenblum; L Cheung; James L Murray; R Bartholomew
Antibody-mediated delivery of tumor necrosis factor (TNF-alpha): improvement of cytotoxicity and reduction of cellular resistance.
Cancer communications 1991;3(1):21-7.
1991: Paul F Mansfield; Michael G Rosenblum; James L Murray; Kyogo Itoh
Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody.
Cancer immunology, immunotherapy : CII 1991;33(4):247-54.
1990: James L Murray; A A Zukiwski; K Mujoo; Michael G Rosenblum
Recombinant alpha-interferon enhances tumor targeting of an antimelanoma monoclonal antibody in vivo.
Journal of biological response modifiers 1990;9(6):556-63.
1990: Yehuda Z Patt; L M Lamki; J Shanken; J M Jessup; Chusilp Charnsangavej; Jaffer A Ajani; Bernard Levin; B Merchant; C Halverson; James L Murray
Imaging with indium111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(7):1246-54.
1990: L M Lamki; A A Zukiwski; L J Shanken; Sewa S Legha; Robert S Benjamin; Carl Plager; D F Salk; R W Schroff; James L Murray
Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen.
Cancer research 1990;50(3 Suppl):904s-908s.
1990: Michael G Rosenblum; James L Murray; S Stuckey; Robert A Newman; S Chaney; Abdul R Khokhar
Modification of methyliminodiacetato-trans-R,R-1,2-diamminocyclohexane platinum(II) pharmacology using a platinum-specific monoclonal antibody.
Cancer chemotherapy and pharmacology 1990;25(6):405-10.
1990: L M Lamki; Yehuda Z Patt; Michael G Rosenblum; L J Shanken; L B Thompson; S A Schweighardt; J M Frincke; James L Murray
Metastatic colorectal cancer: radioimmunoscintigraphy with a stabilized In-111-labeled F(ab')2 fragment of an anti-CEA monoclonal antibody.
Radiology 1990;174(1):147-51.
1989: James L Murray; Eugenie S Kleinerman; Joan E. Cunningham; J R Tatom; K Andrejcio; J Lepe-Zuniga; L M Lamki; Michael G Rosenblum; H Frost; Jordan U Gutterman
Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(12):1915-25.
1989: K H Lee; Moshe Talpaz; J M Rothberg; James L Murray; Nicholas Papadopoulos; Carl Plager; R Benjamin; D Levitt; Jordan U Gutterman
Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(11):1726-32.
1989: Eugenie S Kleinerman; James L Murray; J S Snyder; Joan E. Cunningham; Isaiah J Fidler
Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine.
Cancer research 1989;49(16):4665-70.
1989: D R Parkinson; Moshe Talpaz; K H Lee; Sewa S Legha; A B Markowitz; Kyogo Itoh; Charles M Balch; James L Murray; A A Zukiwski; Robert S Benjamin
Interleukin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M.D. Anderson Cancer Center.
Cancer treatment reviews 1989;16 Suppl A():39-48.
1989: D R McCready; Charles M Balch; Isaiah J Fidler; James L Murray
Lack of comparability between binding of monoclonal antibodies to melanoma cells in vitro and localization in vivo.
Journal of the National Cancer Institute 1989;81(9):682-7.
1989: M Frontiera; James L Murray; L Lamki; J Thomas; W Satterlee; R Schmelter; Michael G Rosenblum; Muhammad B Khazaeli; M W Unger; William A Robinson
Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma.
Clinical nuclear medicine 1989;14(5):357-66.
1988: James L Murray; L M Lamki; L J Shanken; M E Blake; Carl Plager; Robert S Benjamin; S Schweighardt; M W Unger; Michael G Rosenblum
Immunospecific saturable clearance mechanisms for indium-111-labeled anti-melanoma monoclonal antibody 96.5 in humans.
Cancer research 1988;48(15):4417-22.
1988: L M Lamki; James L Murray; Michael G Rosenblum; Yehuda Z Patt; R Joseph Babaian; M W Unger
Effect of unlabelled monoclonal antibody (MoAb) on biodistribution of 111indium labelled (MoAb).
Nuclear medicine communications 1988;9(8):553-64.
1988: Yehuda Z Patt; L M Lamki; T P Haynie; M W Unger; Michael G Rosenblum; A Shirkhoda; James L Murray
Improved tumor localization with increasing dose of indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(8):1220-30.
1988: Michael G Rosenblum; L M Lamki; James L Murray; Dennis J Carlo; Jordan U Gutterman
Interferon-induced changes in pharmacokinetics and tumor uptake of 111In-labeled antimelanoma antibody 96.5 in melanoma patients.
Journal of the National Cancer Institute 1988;80(3):160-5.
1988: James L Murray; S E Stuckey; J K Pillow; Michael G Rosenblum; Jordan U Gutterman
Differential in vitro effects of recombinant alpha-interferon and recombinant gamma-interferon alone or in combination on the expression of melanoma-associated surface antigens.
Journal of biological response modifiers 1988;7(2):152-61.
1987: R Joseph Babaian; James L Murray; L M Lamki; T P Haynie; Evan M Hersh; Michael G Rosenblum; H J Glenn; M W Unger; Dennis J Carlo; A C von Eschenbach
Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276.
The Journal of urology 1987;137(3):439-43.
1987: James L Murray; Michael G Rosenblum; L Lamki; T P Haynie; H J Glenn; Carl Plager; M W Unger; Dennis J Carlo; Evan M Hersh
Radioimmunoimaging in malignant melanoma patients with the use of indium-111-labeled antimelanoma monoclonal antibody (ZME-018) to high-molecular-weight antigen.
NCI monographs : a publication of the National Cancer Institute 1987;(3):3-9.
1987: James L Murray; Michael G Rosenblum; L Lamki; H J Glenn; Z Krizan; Evan M Hersh; Carl Plager; Richard Bartholomew; M W Unger; Dennis J Carlo
Clinical parameters related to optimal tumor localization of indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1987;28(1):25-33.
1985: Z Krizan; James L Murray; Evan M Hersh; Michael G Rosenblum; H J Glenn; C R Gschwind; Dennis J Carlo
Increased labeling of human melanoma cells in vitro using combinations of monoclonal antibodies recognizing separate cell surface antigenic determinants.
Cancer research 1985;45(10):4904-9.
1985: Michael G Rosenblum; James L Murray; T P Haynie; H J Glenn; M F Jahns; Robert S Benjamin; J M Frincke; Dennis J Carlo; Evan M Hersh
Pharmacokinetics of 111In-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma.
Cancer research 1985;45(5):2382-6.
1985: James L Murray; Michael G Rosenblum; R E Sobol; Richard Bartholomew; Carl Plager; T P Haynie; M F Jahns; H J Glenn; L Lamki; Robert S Benjamin
Radioimmunoimaging in malignant melanoma with 111In-labeled monoclonal antibody 96.5.
Cancer research 1985;45(5):2376-81.